Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts. Show more

Location: 890 Winter Street, Waltham, MA, 02451, United States | Website: https://upstreambio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

617.6M

52 Wk Range

$5.14 - $29.46

Previous Close

$11.84

Open

$11.68

Volume

164,986

Day Range

$11.45 - $11.85

Enterprise Value

161M

Cash

431.4M

Avg Qtr Burn

-20.69M

Insider Ownership

14.84%

Institutional Own.

89.41%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.